VIR Vir Biotechnology Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: VIR

Price (delayed)

$7.95

Market cap

$1.07B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.59

Enterprise value

$930.34M

Vir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are ...

Highlights
The debt has contracted by 10% YoY and by 2.1% from the previous quarter
VIR's gross margin is up by 6% year-on-year and by 3.8% since the previous quarter
VIR's quick ratio has surged by 85% year-on-year but it is down by 16% since the previous quarter
VIR's revenue has plunged by 95% YoY and by 27% from the previous quarter
The company's gross profit has shrunk by 94% YoY and by 25% QoQ
Sector: Healthcare
Industry: Biotechnology
Peers: OCX OGEN OLMA OMER

Key stats

What are the main financial stats of VIR
Market
Shares outstanding
135.03M
Market cap
$1.07B
Enterprise value
$930.34M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.67
Price to sales (P/S)
12.37
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.8
Earnings
Revenue
$86.18M
EBIT
-$628.14M
EBITDA
-$601.03M
Free cash flow
-$800.36M
Per share
EPS
-$4.59
Free cash flow per share
-$5.97
Book value per share
$11.82
Revenue per share
$0.64
TBVPS
$14.01
Balance sheet
Total assets
$1.92B
Total liabilities
$328.82M
Debt
$111.67M
Equity
$1.59B
Working capital
$1.41B
Liquidity
Debt to equity
0.07
Current ratio
9.05
Quick ratio
8.75
Net debt/EBITDA
0.24
Margins
EBITDA margin
-697.4%
Gross margin
96.8%
Net margin
-713.7%
Operating margin
-794%
Efficiency
Return on assets
-27.7%
Return on equity
-34.9%
Return on invested capital
-42.7%
Return on capital employed
-36%
Return on sales
-728.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

VIR stock price

How has the Vir Biotechnology stock price performed over time
Intraday
-0.13%
1 week
-11.37%
1 month
-20.5%
1 year
-68.33%
YTD
-20.97%
QTD
-21.52%

Financial performance

How have Vir Biotechnology's revenue and profit performed over time
Revenue
$86.18M
Gross profit
$83.42M
Operating income
-$684.31M
Net income
-$615.06M
Gross margin
96.8%
Net margin
-713.7%
The company's operating income has shrunk by 182% YoY
VIR's revenue has plunged by 95% YoY and by 27% from the previous quarter
The company's gross profit has shrunk by 94% YoY and by 25% QoQ
The net margin has contracted by 41% from the previous quarter

Growth

What is Vir Biotechnology's growth rate over time

Valuation

What is Vir Biotechnology stock price valuation
P/E
N/A
P/B
0.67
P/S
12.37
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.8
The EPS has declined by 2% since the previous quarter
VIR's price to book (P/B) is 84% lower than its 5-year quarterly average of 4.2 and 48% lower than its last 4 quarters average of 1.3
Vir Biotechnology's equity has decreased by 23% YoY and by 5% from the previous quarter
VIR's revenue has plunged by 95% YoY and by 27% from the previous quarter
The price to sales (P/S) is 73% lower than the 5-year quarterly average of 45.3 but 24% higher than the last 4 quarters average of 10.0

Efficiency

How efficient is Vir Biotechnology business performance
The return on invested capital has dropped by 173% year-on-year but it rose by 6% since the previous quarter
The return on sales has declined by 31% since the previous quarter
Vir Biotechnology's return on assets has decreased by 13% QoQ
Vir Biotechnology's return on equity has decreased by 9% QoQ

Dividends

What is VIR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VIR.

Financial health

How did Vir Biotechnology financials performed over time
VIR's quick ratio has surged by 85% year-on-year but it is down by 16% since the previous quarter
The current ratio has soared by 84% YoY but it has contracted by 16% from the previous quarter
The debt is 93% less than the equity
Vir Biotechnology's equity has decreased by 23% YoY and by 5% from the previous quarter
The debt to equity rose by 17% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.